Description: Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.
Home Page: www.annovisbio.com
101 Lindenwood Drive
Malvern,
PA
19355
United States
Phone:
(484) 875-3192
Officers
| Name | Title |
|---|---|
| Dr. Maria L. Maccecchini Ph.D. | Founder, CEO, President, Interim Principal Financial Officer & Executive Director |
| Mr. Mark K. White | Chief Business Officer & Director |
| Dr. Cheng Fang Ph.D. | Senior Vice President of Research & Development |
| Ms. Eve M. Damiano M.S., RAC | Senior Vice President of Regulatory Operations |
| Ms. Melissa Gaines | Senior Vice President of Clinical Operations |
| Mr. Blake Jensen | Head of Quality |
| Ms. Hilda Maibach | Senior Vice President of Statistics |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 11.227 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 6 |